Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Baskent University

Status and phase: Completed; Phase 4

Conditions: Type 2 Diabetes Mellitus; Obesity

Treatments: Drug: rosiglitazone

Study type: Interventional

Funder types: Other

Identifiers

NCT00522470

KA 06/299

Details and patient eligibility

About

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Sex: Female

Ages: 45 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• newly diagnosed, drug naive women with type 2 diabetes

Exclusion criteria

• presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
• presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders